CLIONA ROONEY to Receptors, Antigen, T-Cell
This is a "connection" page, showing publications CLIONA ROONEY has written about Receptors, Antigen, T-Cell.
Connection Strength
3.966
-
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
Score: 0.517
-
Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3499-3509.
Score: 0.431
-
Peripheral blood-derived virus-specific memory stem T cells mature to functional effector memory subsets with self-renewal potency. J Immunol. 2015 Jun 01; 194(11):5559-67.
Score: 0.381
-
Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein-Barr Virus-Specific T-Cells. Int J Mol Sci. 2023 Oct 31; 24(21).
Score: 0.172
-
Banking on virus-specific T cells to fulfill the need for?off-the-shelf cell therapies. Blood. 2023 02 23; 141(8):877-885.
Score: 0.164
-
A Costimulatory CAR Improves TCR-based Cancer Immunotherapy. Cancer Immunol Res. 2022 04 01; 10(4):512-524.
Score: 0.154
-
A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells. J Transl Med. 2019 07 24; 17(1):240.
Score: 0.128
-
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 03; 7(3):363-375.
Score: 0.123
-
In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
Score: 0.120
-
Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther. 2018 06; 18(6):653-664.
Score: 0.118
-
Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo. Nat Commun. 2018 04 10; 9(1):1325.
Score: 0.117
-
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247.
Score: 0.112
-
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471.
Score: 0.112
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.111
-
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
Score: 0.110
-
Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. J Immunol. 2017 07 01; 199(1):348-362.
Score: 0.110
-
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
Score: 0.107
-
Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
Score: 0.103
-
Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells. J Immunother. 2014 Oct; 37(8):407-15.
Score: 0.092
-
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
Score: 0.086
-
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6.
Score: 0.074
-
Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother. 2007 Jul-Aug; 30(5):506-16.
Score: 0.055
-
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30.
Score: 0.055
-
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother. 2006 Jan-Feb; 29(1):21-31.
Score: 0.050
-
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005 Nov; 12(5):933-41.
Score: 0.048
-
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing. Cytotherapy. 2024 03; 26(3):266-275.
Score: 0.044
-
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002 Mar 15; 99(6):2009-16.
Score: 0.038
-
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26.
Score: 0.028
-
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
Score: 0.028
-
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
Score: 0.024
-
CMV-specific T cells generated from na?ve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015 Apr 29; 7(285):285ra63.
Score: 0.024
-
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
Score: 0.024
-
Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy. 2014 Sep; 16(9):1257-69.
Score: 0.023
-
Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. J Immunother. 2013 Jan; 36(1):3-10.
Score: 0.020
-
Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet. 2011 Apr 15; 20(R1):R93-9.
Score: 0.018
-
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8.
Score: 0.017
-
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87.
Score: 0.016
-
Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. Cancer Res. 2007 Sep 01; 67(17):8335-43.
Score: 0.014